Is CVS a Buy? What to Consider in 2026
Short answer
The bull case for CVS Health (CVS) rests on Integrated model under one roof: CVS is one of few companies that combines an insurer (Aetna), a pharmacy benefit manager (Caremark), and a retail pharmacy chain. Revenue (annual run-rate) is ~$400 billion; FY2026 guidance at least ~$405 billion. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. Whether CVS is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
CVS Health runs three reporting segments. Health Care Benefits is the Aetna insurance business, which earns premiums from roughly 26 million medical members and profits when claims (the medical benefit ratio) stay below what it collects. Health Services is built around the Caremark pharmacy benefit manager, which negotiates drug prices and manages pharmacy claims for health plans and employers and generated over $48 billion of revenue in Q1 2026. Pharmacy and Consumer Wellness is the familiar retail footprint of CVS drugstores, which makes money filling prescriptions and selling front-of-store health and consumer goods, with same-store prescription volumes up nearly 7% in Q1 2026. The modern shape of the company traces to its 2018 acquisition of Aetna for roughly $70 billion, which combined a national insurer with the existing pharmacy and PBM businesses and added substantial debt. After a difficult stretch in 2023 and 2024 when Aetna's medical costs ran well above plan and the stock fell sharply, David Joyner became CEO in October 2024 and was later named board chair; he has framed the recovery as restoring pricing discipline at Aetna while running the integrated model more tightly. Total revenue now runs around $400 billion annually, among the largest of any U.S. company.
What's the case for buying CVS?
Integrated model under one roof
CVS is one of few companies that combines an insurer (Aetna), a pharmacy benefit manager (Caremark), and a retail pharmacy chain. Bulls argue this vertical integration lets it capture margin across the drug-spending chain and steer members toward its own assets. When the pieces work together, the model can be more resilient than any single-segment competitor.
Turnaround and improving Aetna margins
After Aetna's medical costs ran far above plan in 2023 and 2024, management has reported several consecutive quarters of improvement. In Q1 2026 the medical benefit ratio fell to ~84.6% from ~87.3% a year earlier, and Health Care Benefits adjusted operating income rose sharply. CVS raised its full-year 2026 adjusted EPS guidance to ~$7.30 to $7.50, signaling growing confidence in the recovery.
Low valuation versus the broad market
CVS trades at a low forward earnings multiple relative to the S&P 500, reflecting investor caution after the prior downturn. Against full-year adjusted EPS guidance near $7.40, the forward multiple is in the mid-teens at a ~$104 share price. Value-oriented investors see this as pricing in continued trouble that the recent results have started to challenge.
Dividend and cash generation
CVS pays a quarterly dividend of ~$0.665 per share, or roughly $2.66 annually, for a yield around 2.5% at recent prices. The company reported a cash position near $14 billion and generates large operating cash flows from its scale. Income-focused investors weigh that payout against the company's substantial debt load.
What are the risks to CVS?
The clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. The Caremark PBM faces intensifying regulatory and political pressure, including FTC litigation, a 2026 House Judiciary antitrust report, state investigations in Florida and elsewhere, and rebate pass-through reform that could compress a core profit pool. The retail pharmacy business faces reimbursement pressure and store closures, and the company carries a large debt balance from the Aetna deal that limits flexibility if the turnaround stalls.
How is CVS valued? (as of 2026-06-27)
- Revenue (annual run-rate): ~$400 billion; FY2026 guidance at least ~$405 billion
- Adjusted EPS (FY2026 guidance): ~$7.30 to $7.50 (Q1 2026 was ~$2.57)
- Aetna medical benefit ratio (Q1 2026): ~84.6%, improved from ~87.3% a year earlier
- Dividend yield: ~2.5% (~$2.66 annual, ~$0.665 quarterly)
- P/E ratio: ~46 trailing (depressed by prior charges); ~14 forward on guidance
- Market cap: ~$133 billion (shares ~$104)
CVS trades at a low forward earnings multiple versus the broad market, which reflects lingering caution after the 2023 to 2024 Aetna downturn rather than current results. The value angle rests on whether improving margins and ~$400 billion of revenue can support the raised guidance. Figures are approximate and tied to the asOf date; verify live quotes and the latest filings before acting.
How do you decide if CVS is a buy?
Rather than asking whether CVS is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CVS indirectly through an index or sector ETF before adding more.
For the full picture, see the CVS stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CVS against your real portfolio and see your actual exposure before deciding.
The bottom line on CVS
The bottom line: CVS Health's story right now is Integrated model under one roof, with revenue (annual run-rate) at ~$400 billion; FY2026 guidance at least ~$405 billion. If you believe that narrative continues, the call is about sizing CVS sensibly and checking overlap with what you own; if you doubt it (the risk: the clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around CVS with Walnut
Use CVS Health as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is CVS a good stock to buy right now?
+
The case for CVS Health right now is Integrated model under one roof, with revenue (annual run-rate) at ~$400 billion; FY2026 guidance at least ~$405 billion. If you believe that thesis holds, CVS is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does CVS Health do?
+
CVS Health runs three reporting segments.
What are the main risks of CVS?
+
The clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. The Caremark PBM faces intensifying regulatory and political pressure, including FTC litigation, a 2026 House Judiciary antitrust report, state investigations in Florida and elsewhere, and rebate pass-through reform that could compress a core profit pool. The retail pharmacy business faces reimbursement pressure and store closures, and the company carries a large debt balance from the Aetna deal that limits flexibility if the turnaround stalls.
Is CVS a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not advice. The bull case is a cheap valuation, a ~2.5% dividend, and an Aetna turnaround that showed real progress in early 2026. The bear case is that medical costs could reaccelerate, PBM reform could compress profits, and debt is high. Both can be true at once.
What does CVS Health do?
+
CVS Health is an integrated healthcare company with three parts: Aetna, a health insurer covering roughly 26 million medical members; Caremark, a pharmacy benefit manager that negotiates drug prices for plans and employers; and CVS retail pharmacies that fill prescriptions and sell front-of-store goods. Combined revenue runs around $400 billion a year.
What is the CVS dividend yield?
+
CVS pays a quarterly dividend of about $0.665 per share, or roughly $2.66 per year. At a share price near $104, that works out to a yield of about 2.5%. Some sources report a slightly higher figure depending on the price and calculation method. Dividends can be changed or suspended by the board at any time.
Why did CVS stock drop?
+
The sharp decline in 2023 and 2024 came mainly from Aetna's medical costs running well above plan, especially in Medicare Advantage, which forced earnings guidance cuts. Added pressure came from PBM regulatory scrutiny, retail reimbursement, and the large debt from the Aetna acquisition. Shares have since recovered as margins improved through early 2026.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell CVS; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.